Genesis Healthcare (GEN) Receives a Hold from Credit Suisse

By Ryan Adsit

In a report released yesterday, A.J. Rice from Credit Suisse maintained a Hold rating on Genesis Healthcare (GENResearch Report), with a price target of $2. The company’s shares closed yesterday at $1.71.

According to, Rice is a 5-star analyst with an average return of 11.5% and a 66.7% success rate. Rice covers the Services sector, focusing on stocks such as AMN Healthcare Services Inc, Quest Diagnostics Inc, and Acadia Healthcare.

Currently, the analyst consensus on Genesis Healthcare is a Moderate Buy with an average price target of $4.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.86 and a one-year low of $0.60. Currently, Genesis Healthcare has an average volume of 294.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genesis Healthcare, Inc. is a holding company, which engages in the provision of inpatient services through skilled nursing and assisted and senior living communites. It also offers rehabilitation and respiratory therapy services. It operates through the following segments: Inpatient, Rehabilitation Therapy, and Other Services.